See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Social Media
Tariffs
South America
Tennis
Donald Trump
Soccer
Floods
Twitter
Hockey
Cricket
Published • loading... • Updated

FGFR2 identified as key driver in KRAS-mutated pancreatic cancer progression

Summary by News Medical
Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation delayed KRAS-mutated PDAC development in mice.

4 Articles

All
Left
Center
1
Right
News MedicalNews Medical
Center

FGFR2 identified as key driver in KRAS-mutated pancreatic cancer progression

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation delayed KRAS-mutated PDAC development in mice.

·United States
Read Full Article
Global HappeningsGlobal Happenings

First step to slow down the pancreas cancer - Global Happenings

It is possible Slow down growth Of one of the most aggressive tumorsthat of pancreasnow a candidate to become the second killer tumor by 2030 by 2030. AND’ Just a first step because the result was obtained in the laboratory on mice And cells of cellsbut it is finally Found a way to slow down its very rapid growth And so far unstoppable. “A race against time“, The researchers led by David Tuveson, director of the Cold Research Center of Cold Spri…

Read Full Article
GEN - Genetic Engineering and Biotechnology News…GEN - Genetic Engineering and Biotechnology News…

Inhibiting FGFR2 Supports Prevention and Delay of Common Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent type of pancreatic cancer, characterized as a highly lethal malignancy that is often preceded by precancerous lesions. These lesions are relatively common, but only a small portion will progress to PDAC.   In a new study published in Cancer Research titled, “FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development,” researchers from Cold Spring Harbor Laboratory (CSHL)…

Read Full Article
BIOENGINEER.ORGBIOENGINEER.ORG

Targeting FGFR2 Could Offer Hope in Preventing or Delaying KRAS-Mutated

FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development In a groundbreaking study published in the journal Cancer Research, researchers have uncovered intriguing insights that could reshape our understanding of pancreatic cancer progression. The focus of the study centers around the FGFR2 protein, with findings suggesting that its expression is markedly heightened in precancerous pancreatic lesions and certain pancreatic ductal …

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

BIOENGINEER.ORG broke the news in on Wednesday, April 2, 2025.
Sources are mostly out of (0)

Similar News Topics

Cold Spring Harbor

Cold Spring Harbor

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal